Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AERAS-402 boost after BCG in healthy adults
NCT02375256Phase 1Completed
- Sponsor
- Aeras Global Vaccine Foundation
- Start
- Oct 2009
- Primary completion
- Dec 2010
- Modality
- Viral Vector Vaccines
01
Overview
Phase 1, randomised, double-blind trial in Tuberculosis (TB) comparing AERAS-402 with Placebo (2 arms). Primary endpoint: Cellular immune responses to AERAS-402 at Day 98. Started Oct 2009; status: completed.
02
Drugs
AERAS-402
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT02375256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02375256.